Vericel Announces U.S. Commercial Availability of NexoBrid (anacaulase-bcdb) for the Treatment of Severe Thermal Burns in Adults

Full commercial launch of NexoBrid marks important first step to becoming the new standard of care for eschar removal in patients with deep partial- and/or full- thickness thermal burns

NexoBrid launch significantly expands the total addressable market for Vericel Burn Care

CAMBRIDGE, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the U.S. commercial availability of NexoBrid (anacaulase-bcdb) for the removal of eschar in adults with deep partial- and/or full-thickness thermal burns.

Eschar removal is a critical first step in the treatment of burns as it can reduce inflammation, stop burn progression, as well as mitigate infections and sepsis. Surgical excision, which is the current standard of care for eschar removal, often results in the removal of viable tissue. NexoBrid selectively targets eschar while preserving viable tissue, enabling more rapid and precise eschar removal, which may reduce the need for subsequent skin grafting and lessen patient trauma.

“We are very pleased to announce the U.S. commercial availability of NexoBrid, as it significantly expands our Burn Care franchise and represents an important paradigm shift in the treatment of severe thermal burns,” said Nick Colangelo, President and CEO of Vericel. “In addition to providing burn surgeons with an important new tool to manage these severely injured patients, NexoBrid will also diversify our revenue stream and enhance our topline earnings.”

Each year, approximately 40,000 people are hospitalized in the U.S. for burn-related injuries, and of those patients, more than 30,000 of them require some level of eschar removal, representing a $300 million addressable market for NexoBrid. NexoBrid can be applied in up to two applications of four hours each. A first application of NexoBrid may be applied to an area of up to 15% body surface area. A second application of NexoBrid may be applied 24 hours later, with a total treated area for both applications of up to 20% Total Body Surface Area (TBSA).

About NexoBrid
NexoBrid (anacaulase-bcdb) is a botanical drug product containing proteolytic enzymes indicated for the removal of eschar in adults with deep partial- and/or full-thickness thermal burns. To learn more about NexoBrid, please visit www.NexoBrid-US.com.

Indication: NexoBrid (anacaulase-bcdb) is indicated for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.
Limitations of Use